Insights

Here’s why Moderna stock soared 125% during the first 6 months of 2021

The COVID-19 vaccine maker has been well rewarded for coming up with a stopgap solution as quickly as it did.
The post Here’s why Moderna stock soared 125% during the first 6 months of 2021 appeared first on The Motley Fool Australia. –

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of biopharma Moderna (NASDAQ: MRNA) advanced 124.9% during the first half of this year, according to S&P Global Market Intelligence. The rally extends gains made since early 2020, when the company emerged as a COVID-19 vaccine contender, and then delivered on that promise later in the year.

So what

It’s a name that needs little in the way of an introduction. Moderna joins Johnson & Johnson (NYSE: JNJ), Novavax (NASDAQ: NVAX), and a partnership between Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) as the core suppliers of the vaccines aimed at curbing the coronavirus contagion. Moderna’s mRNA-1273 was approved by the FDA for emergency use in December of last year, though investors were willing to reward the company before and after that green light.

And well they should. Product revenue for the developmental company grew from essentially nothing a year earlier to $1.7 billion for the three-month stretch ending in March, with all of it consisting of COVID vaccine sales.

In the meantime, the company has continued to expand on the potential of mRNA-1273 as well as move forward with trials of other vaccine and treatment candidates. It also has other trials underway, such as testing of its mRNA technology as a means of treating cancer, autoimmune disease, and cardiovascular disease — though for the foreseeable future, evolving strains of COVID will keep the organization busy.

Now what

It’s tempting to step into (or stick with) one of the market’s hottest biotech stocks that’s performing well for all the right reasons. The pandemic could be with us for a while — perhaps permanently if new strains keep surfacing — and Moderna’s answer thus far appears to be the least problematic. J&J’s vaccine has been linked to the development of Guillain-Barre syndrome, while Pfizer’s might lead to heart inflammation in rare cases. Moderna’s mRNA solution can also cause the same myocarditis, although it’s highly effective, and if nothing else, it’s increasingly available in an environment where something is better than nothing.

With shares up nearly 900% since the coronavirus outbreak went worldwide last year, though, existing shareholders may want to start thinking about an exit plan.

While Moderna has provided a beacon of hope, its effort and potential are not only well publicized and fully priced into shares, but they might also be more than priced in. Even the usually aggressive analyst community agrees that shares are only worth on the order of $177 right now, while the stock is trading at a frothy $238.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Here’s why Moderna stock soared 125% during the first 6 months of 2021 appeared first on The Motley Fool Australia.

Should you invest $1,000 in Moderna right now?

Before you consider Moderna, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Moderna wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

Does This Shocking CDC Statement Mean Trouble for Pfizer and Moderna?

With COVID-19 variant threats rising, why are vaccine stocks falling?

Why Moderna shares surged 27% in June

Why Moderna stock jumped 6% Tuesday

Is this the secret ingredient that could make Moderna shareholders rich?

James Brumley has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
Trade The US Market With ZERO Brokerage* + FREE Access To Trading Ideas & Value Analysis Tools. Click Here!